Sosei Heptares to present at 41st Annual J.P. Morgan Healthcare Conference
December 20, 2022 01:30 ET
|
Sosei Group Corporation
TOKYO and CAMBRIDGE, United Kingdom, Dec. 20, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) announces its President & CEO Chris Cargill will present at the 41st...
Sosei Heptares and Lilly Enter Multi-target Collaboration and License Agreement in Diabetes and Metabolic Diseases
December 15, 2022 19:01 ET
|
Sosei Group Corporation
New agreement leverages Sosei Heptares’ GPCR-focused structure-based drug design capabilities and Lilly’s extensive development, commercialization and therapeutic area expertiseSosei Heptares eligible...
Sosei Heptares Enters R&D Agreements with the University of Oxford and KU Leuven to Identify and Validate Key GPCRs Driving Gastrointestinal and Immune Disorders
December 08, 2022 01:30 ET
|
Sosei Group Corporation
Agreements build on Sosei Heptares’ Target Identification and Validation strategy and translational medicine approach to drug discovery, enabling the Company to rapidly prioritize disease-relevant...
Sosei Heptares Operational Highlights and Consolidated Results for the Third Quarter and First Nine Months of 2022
November 11, 2022 01:30 ET
|
Sosei Group Corporation
TOKYO and CAMBRIDGE, United Kingdom, Nov. 11, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its consolidated...
Sosei Heptares’ President & CEO and Head of UK R&D to Participate in a ‘Fireside Chat’ at the Jefferies London Healthcare Conference 2022
November 09, 2022 03:00 ET
|
Sosei Group Corporation
TOKYO and CAMBRIDGE, United Kingdom, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) announces its President & CEO Chris Cargill and Matt Barnes, Head of UK...
Sosei Heptares’ Partner Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1117568 in Adults with Schizophrenia
October 27, 2022 19:05 ET
|
Sosei Group Corporation
NBI-1117568 is an Investigational, First-in-Class, Muscarinic M4 Selective Agonist TOKYO and CAMBRIDGE, United Kingdom, Oct. 28, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”;...
Sosei Heptares to host R&D Day highlighting its innovative R&D and translational medicine approaches to drug discovery and strong pipeline momentum
September 27, 2022 02:30 ET
|
Sosei Group Corporation
TOKYO and CAMBRIDGE, United Kingdom, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) will hold an R&D Day on Thursday, 13 October 2022, at 3:30 pm JST. The...
Sosei Heptares Wins Licensing Deal of the Year and Executive of the Year at the Inaugural Informa Pharma Intelligence Awards Japan
September 01, 2022 19:05 ET
|
Sosei Group Corporation
TOKYO and CAMBRIDGE, United Kingdom, Sept. 02, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565), an international biopharmaceutical company and world-leader in...
Sosei Heptares Operational Highlights and Consolidated Results for the Second Quarter and First Half of 2022
August 10, 2022 02:45 ET
|
Sosei Group Corporation
TOKYO, Japan and CAMBRIDGE, United Kingdom, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Sosei Group Corporation (“the Company”; TSE: 4565) provides an update on operational activities and reports its...
Sosei Heptares’ Oral, Selective M4 Receptor Agonist Advancing into Phase 2 Clinical Development under Multi-Program Collaboration with Neurocrine Biosciences
August 04, 2022 19:05 ET
|
Sosei Group Corporation
Neurocrine to conduct placebo-controlled Phase 2 study to investigate NBI-1117568 (formerly HTL-0016878) as a potential new treatment for schizophrenia Clinical development milestone triggers payment...